U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

Substitute for form 1449/PTO			Complete if Known			
INFORMATION DISCLOSURE			Application Number	10/576,575	5	
STATEMENT BY APPLICANT				Filing Date	April 20, 20	006
Date Submitted: October 1, 2007			First Named Inventor	Robyn Lyni	ne Ward	
	Date Submitted, October 1, 2007			Art Unit	1634	
(use as many sheets as necessary)			Examiner Name	**************************************	Amanda Shaw	
Sheet	1	of	2	Attorney Docket Number	037775-01	07

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
		Number-Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear	
	A5	US-2003/124600 A1	07-03-2003	Sidranksy		
	A6	US-6,235,474 B1	05-22-2001	Feinberg		
l						

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
			_				

FOREIGN PATENT DOCUMENTS							
Examiner Cite Foreign Patent Document Initials* No.1 Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	A7	WO 01/75175 A2	10-11-2001	University of Southern California			
	A8	WO 2005/001141 A3	01-06-2005	Epigenomics AG			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./

Examiner		Date	03/09/2010
Signature	/Amanda Shaw/	Considered	00/05/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
INFORMATION DISCLOSURE Application

Date Submitted: October 1, 2007

(use as many sheets as necessary)

2 of 2

Sheet

Complete if Known					
Application Number	10/576,575				
Filing Date	April 20, 2006				
First Named Inventor	Robyn Lynne Ward				
Art Unit	1634				
Examiner Name	University Amanda Shaw				
Attorney Docket Number	037775-0107				

	MANAGEM COMMUNICATION	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A9	ISSA et al.; "Accelerated Age-related CpG Island Methylation in Ulcerative Colitis ¹ ;" Cancer Research, Vol. 61, No. 9, May 1, 2001; pp. 3573-3577	
	A10	HIBI et al.; "A Cancer-prone Case with a Background of Methylation of <i>p16</i> Tumor Suppressor Gene;" Clinical Cancer Research; Vol. 9, No. 3; March 1, 2003; pp. 1053-1056	Calculation of a secure
	A11	WONG et al.; "Quantitative Analysis of Tumor-derived Methylated <i>P161NK4a</i> Sequences in Plasma, Serum, and Blood Cells of Hepatocellular Carcinoma Patients ¹ ;" Clinical Cancer Research; Vol. 9, No. 3, March 2003; pp. 1047-1052;	
	A12	WIDSCHWENDTER et al.; "The Potential Prognostic, Predictive, and Therapeutic Values of DNA Methylation in Cancer ¹ ;" Clinical Cancer Research; An Official Journal of the American Association for Cancer Research; Vol. 8, No. 1, January 2002; pp. 17-21	
AAAA MARKA YIII IYAAAA AAAAAAAAAAAAAAAAAAAAAAAAA	A13	HARDEN et al.; "Molecular assessment of histologically negative lymph nodes and correlation with survival in surgically resected stage I lung cancer using promoter methylation of multiple genes;" Proceedings of the American Association for Cancer Research Annual Meeting; Vol. 43; March 2002; page 221	
	A14	ESTELLER et al.; "Analysis of <i>Adenomatous Polyposis Coli</i> Promoter Hypermethylation in Human Cancer ¹ ;" Cancer Research, American Association for Cancer Research; Vol. 60, No. 16; August 15, 2000; pp. 4366-4371;	
	A15	GAZZOLI et al.; "A Hereditary Nonpolyposis Colorectal Carcinoma Case Associated with Hypermethylation of the MLH1 Gene in Normal Tissue and Loss of Heterozygosity of the Unmethylated Allele in the Resulting Microsatellite Instability-High Tumor ¹ ;" Cancer Research, Vol. 62, No. 14; July 15, 2002; pp. 3925-3928	
4444	A16	CUI et al.; "Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation of H19 and IGF2 ¹ ;" Cancer Research, American Association for Cancer Research; Vol. 62; November 15, 2002; pp. 6442-6446	
	A17	SUTER et al.; "Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue;" International Journal of Colorectal Disease, Springer Verlag, Berlin, DE, Vol. 19, No. 2, March 2004; pp. 95-101	
	A18	European Search Report (EP 04 78 9594); Date of Mailing: July 3, 2007; 6 pages	
			And the second s
	Laboration of Assessment		Name of Persons and Persons an

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./

Contraction of the Contraction o			
Examiner Signature	/Amanda Shaw/	Date Considered	03/09/2010
8		TO SECURITION OF THE PROPERTY	AND DESCRIPTION OF THE PROPERTY OF THE PROPERT

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.